<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">METHAZOLAMIDE</span><br/>(meth-a-zoe'la-mide)<br/><span class="topboxtradename">Neptazane<br/></span><b>Classifications:</b> <span class="classification">eye preparation</span>; <span class="classification">carbonic anhydrase inhibitor</span>; <span class="classification">sulfonamide derivative</span>; <span class="classification">anti-glaucoma</span><br/><b>Prototype: </b>Acetazolamide<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Nonbactericidal sulfonamide derivative similar to acetazolamide but with slower onset and longer duration of action. Appears
         to cause more drowsiness and fatigue than acetazolamide does, and has less diuretic activity.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits carbonic anhydrase activity in eye by reduces rate of aqueous humor formation with consequent lowering of intraocular
         pressure.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive treatment in chronic simple (open-angle) glaucoma and secondary glaucoma and preoperatively in acute angle-closure
         glaucoma when delay of surgery is desired in order to lower intraocular pressure. May be used concomitantly with miotic and
         osmotic agents.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Glaucoma due to severe peripheral anterior synechiae, severe or absolute glaucoma, hemorrhagic glaucoma; hypokalemia, hyponatremia.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category C), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Glaucoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50100 mg b.i.d. or t.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with meals to minimize GI distress.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Malaise, drowsiness, fatigue, lethargy. <span class="typehead">GI:</span> Mild GI disturbance, anorexia. <span class="typehead">CNS:</span> Headache, vertigo, paresthesias, mental confusion, depression. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Renal excretion of <span class="classification">amphetamines</span>, <b>ephedrine,</b> <b>flecainide,</b> <b>quinidine,</b> <b>procainamide,</b> <span class="classification">tricyclic antidepressants</span> may be decreased, thereby enhancing or prolonging their effects; increases renal excretion of <b>lithium;</b> excretion of <b>phenobarbital</b> may be increased; <b>amphotericin B,</b> <span class="classification">corticosteroids</span> may add to potassium loss; hypokalemia caused by methazolamide may predispose patients on <span class="classification">digitalis glycosides</span> to <b>digitalis</b> toxicity; patients on high doses of <span class="classification">salicylates</span> are at higher risk for <span class="classification">salicylate</span> toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Slowly absorbed from GI tract. <span class="typehead">Onset:</span> 24 h. <span class="typehead">Peak:</span> 68 h. <span class="typehead">Duration:</span> 1018 h. <span class="typehead">Distribution:</span> Distributed throughout body, concentrating in RBCs, plasma, and kidneys; crosses placenta. <span class="typehead">Metabolism:</span> Partially metabolized in liver. <span class="typehead">Elimination:</span> Excreted primarily in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Supervise ambulation in older adult, since drug may cause vertigo.</li>
<li>Assess patient's ability to perform ADL since drug may cause fatigue and lethargy.</li>
<li>Lab tests: Obtain periodic serum electrolytes, especially in older adults. Monitor lithium levels with concurrent administration
            of lithium and methazolamide.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that drug may cause drowsiness. Advise caution with hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>